Marie-Pier Gauthier,Jennifer H Law,Lisa W Le et al.
Marie-Pier Gauthier et al.
Introduction: Real-world evidence is important in regulatory and funding decisions. Manual data extraction from electronic health records (EHRs) is time-consuming and challenging to maintain. Automated extraction using na...
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report [0.03%]
关于德瓦卢单抗联合铂类-依托泊苷一线治疗广泛期小细胞肺癌的脑转移对其疗效和预后影响的卡斯皮安研究简报
Yuanbin Chen,Luis Paz-Ares,Niels Reinmuth et al.
Yuanbin Chen et al.
Introduction: In the phase 3 study involving the use of durvalumab with or without tremelimumab in combination with platinum-based chemotherapy in untreated extensive-stage SCLC (CASPIAN study), first-line durvalumab plus...
Percutaneous Image-Guided Biopsy for a Comprehensive Hybridization Capture-Based Next-Generation Sequencing in Primary Lung Cancer: Safety, Efficacy, and Predictors of Outcome [0.03%]
用于全面的下一代测序的经皮影像引导肺原发肿瘤活检的安全性、有效性及预后因素分析
Ahmed Elsakka,Elena N Petre,Fourat Ridouani et al.
Ahmed Elsakka et al.
Introduction: To evaluate factors associated with successful comprehensive genomic sequencing of image-guided percutaneous needle biopsies in patients with lung cancer using a broad hybrid capture-based next-generation se...
Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report [0.03%]
普拉替尼治疗伴发获得性RET融合的EGFR突变型脑膜转移NSCLC的疗效：简短报告
Zichen Zhao,Chao Su,Weigang Xiu et al.
Zichen Zhao et al.
Introduction: RET is well known as an important driver gene in NSCLC. Moreover, RET is a rare acquired resistance mechanism to EGFR-mutant NSCLC. Only 36 NSCLC cases of coexistence of EGFR and RET were reported previously...
Brief Report on Teleconsultation in Lung Cancer: Toward a Semiotic Paradigm Shift? [0.03%]
肺癌远程咨询报告：迈向符号学范式转变？
Quentin Dominique Thomas,Clémence Basse,Yaniss Belaroussi et al.
Quentin Dominique Thomas et al.
Introduction: Telehealth is taking an increasingly important part of medicine. This practice change is being accelerated by the pandemic linked to coronavirus disease 2019. Oncology is a medical specialty for which this p...
Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in ALK-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief Report [0.03%]
ALK重排型肺癌腺癌在接受序贯式ALK抑制剂治疗后发生神经内分泌转化的基因组和转录组分析简报
Jie Huang,Shi-Ling Zhang,Chaozheng Zhou et al.
Jie Huang et al.
Introduction: Neuroendocrine (NE) transformation has been reported in patients with ALK-rearranged NSCLC after ALK inhibition, but unlike EGFR-mutant NSCLC, the exact mechanism of NE transformation in ALK-rearranged NSCLC...
Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 2021 [0.03%]
2015至2021年美国晚期/转移性非鳞状非小细胞肺癌患者的生物标志物检测情况
Lisa M Hess,Peter M Krein,Diane Haldane et al.
Lisa M Hess et al.
Introduction: NSCLC is a solid tumor with a growing number of actionable biomarkers that may inform treatment. Current guidelines recommend a broad, panel-based approach be taken to identify actionable markers. This retro...
Severe Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial [0.03%]
安罗替尼联合同步放化疗治疗III期NSCLC的ALTER-L042 I期临床研究中的严重肺毒性反应
Hui Zhu,Wenxiao Jia,Xuquan Jing et al.
Hui Zhu et al.
Introduction: Anlotinib has brought about marked progression-free survival and overall survival benefit compared with placebos as third-line or further treatment in advanced NSCLC. Nevertheless, the safety and efficacy of...
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC [0.03%]
恩曲替尼治疗ROS1阳性非小细胞肺癌的长期有效性和安全性评估研究
Alexander Drilon,Chao-Hua Chiu,Yun Fan et al.
Alexander Drilon et al.
Introduction: Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion-positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, w...
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience [0.03%]
奥希替尼高剂量治疗EGFR突变NSCLC患者的中枢神经系统进展的多中心研究经验
A J Piper-Vallillo,Julia K Rotow,Jacqueline V Aredo et al.
A J Piper-Vallillo et al.
Introduction: This multicenter review evaluated the efficacy and safety of osimertinib dose escalation for central nervous system (CNS) progression developing on osimertinib 80 mg in EGFR-mutant NSCLC. ...